Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials.
about
Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathyComparison of multiplex ligation dependent probe amplification to immunohistochemistry for assessing HER-2/neu amplification in invasive breast cancer.Trastuzumab-associated cardiotoxicity.Trastuzumab use in breast cancer: clinical issues.Evaluation of four techniques using intensity-modulated radiation therapy for comprehensive locoregional irradiation of breast cancer.Cardiovascular complications of breast cancer therapy in older adultsDilated cardiomyopathy following trastuzumab chemotherapy.Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin.Antibody Therapeutics in Oncology.Heme oxygenase-1 regulates mitochondrial quality control in the heart.Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?Human anti-ErbB2 immunoagents--immunoRNases and compact antibodies.Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer.Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells.Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy.Additive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression in vivo.Improving prediction of cardiovascular complications of cancer therapy: what does the future hold?Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors.The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy.Androgen receptors are frequently expressed in mammary and extramammary Paget's disease.Mitral regurgitation due to papillary muscle dyssynchrony during trastuzumab treatment.A novel ErbB2 epitope targeted by human antitumor immunoagents
P2860
Q28593656-4A826296-1EB7-40EC-BB45-C2AE6C609136Q33253893-59C96841-73B6-4498-A537-03E25CFB7687Q34867708-26D2DC28-5529-438B-B5A3-D0ECE4009C25Q35039495-7F618332-D184-49B6-89D3-0A6387A850F0Q35565798-2C94B3EC-2A16-4A7B-AD93-81E15349FBD5Q35584686-35931360-6EA3-44B9-9E7F-8E99879B6B90Q35732533-2BE2A303-F7D1-4E30-AA5A-AEE20D88980BQ36610604-78304D7B-954B-436D-95F3-48C92349D79CQ36791878-16FE5755-B397-4EB5-B5E1-7EED60A449A7Q36819774-1AB245B1-D7C3-474C-BAA9-8495BEC43461Q37131070-143CD43D-E1C8-4908-9D5D-B65840F59BFFQ37394278-818160AE-9D9C-43A5-923C-53E4E5EBA787Q37577633-1F4B0A48-D5E5-42C3-B69C-BF95D9B81CEAQ37586081-68BAE038-5DA2-49CC-B7FC-6C931F61DA61Q37768070-67793D65-0F62-4866-B515-4A9455198587Q38954660-5DF335D6-8F07-4255-AE97-4D40634F21DBQ38978030-BF2F7498-7752-4E22-AC09-8691F1030AA7Q39335759-5F51B0F8-BC51-4E9D-ADDD-F3AAFEA2B24EQ39468098-926F0442-48AF-4171-B060-36836BE433ECQ46269647-3647ACD3-93AF-4B5E-8C47-3ACA386A226EQ46513913-DA0F7048-DCA0-450C-AA75-404033D554BEQ50687140-11022C1A-25EE-411D-9919-B50ED829803BQ57628597-6A01FB8E-78F7-4609-80C9-5D66263F4BA4
P2860
Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Cardiac toxicity of trastuzuma ...... the design of adjuvant trials.
@ast
Cardiac toxicity of trastuzuma ...... the design of adjuvant trials.
@en
Cardiac toxicity of trastuzumab
@nl
type
label
Cardiac toxicity of trastuzuma ...... the design of adjuvant trials.
@ast
Cardiac toxicity of trastuzuma ...... the design of adjuvant trials.
@en
Cardiac toxicity of trastuzumab
@nl
prefLabel
Cardiac toxicity of trastuzuma ...... the design of adjuvant trials.
@ast
Cardiac toxicity of trastuzuma ...... the design of adjuvant trials.
@en
Cardiac toxicity of trastuzumab
@nl
P1433
P1476
Cardiac toxicity of trastuzuma ...... the design of adjuvant trials.
@en
P2093
J A Sparano
P356
10.1016/S0093-7754(01)90189-7
P433
P577
2001-02-01T00:00:00Z